{"entity":{"id":"nct05399654","kind":"trial","name":"A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TAC-001 run by Tallac Therapeutics, of unknown status on the registry.","summary":"A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05399654 by Tallac Therapeutics, with 72 participants planned, started 2022-06-28. Conditions recorded: Advanced or Metastatic Solid Tumors. Interventions recorded: TAC-001.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05399654","url":"https://clinicaltrials.gov/study/NCT05399654"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tac-001"],"companies":["tallac-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05399654","phase":"1/2","setting":"A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors","sponsor":"Tallac Therapeutics","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05399654/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tac-001","kind":"drug","name":"TAC-001","route":"/drugs/tac-001/"}],"company":[{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/"}]}}